Document is current

Article History

Received: 17 September 2023

Accepted: 2 March 2024

First Online: 14 March 2024

Declarations

:

: The study was approved by the local ethics committee of Bern/Switzerland (file number 2020–02274).

: Not applicable.

: AF has undertaken consultancy/presentations for AbbVie, Astra-Zeneca, BMS, Eli-Lilly, Galapagos, Novartis, Pfizer, Sandoz and received grant/research support from AbbVie, BMS, Pfizer, Galapagos. BF has undertaken consultancy for Novartis, Roche, BMS, Galapagos, Servier, UCB, Zura Bio, and received grant/research support from Janssen, Roche, Galapagos, Servier. BMa has consultancies with Novartis, Boehringer Ingelheim, Janssen-Cilag, GSK, Otsuka, has /had grants/research support from AbbVie, Protagen, Novartis Biomedical Research, Boehringer Ingelheim, received speaker fees from Boehringer-Ingelheim, Novartis, GSK as well as congress support from Medtalk, Pfizer, Roche, Actelion, Mepha, and MSD. In addition, BMa has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143). FK is a shareholder of Roche, consultant of Actelion, BMS, Boehringer-Ingelheim, and Pfizer, has grant/research support from Gilead, Pfizer and Roche, is employed by Roche and was previously employed by Novartis. LC reports research/non-financial support, advisory fee and stock ownership from: Gilead Sciences, F. Hoffmann-La Roche, Novartis, Pfizer, Bristol-Myers Squibb, Sanofi; BMoe, SA, and SK declare no competing interests.